Biocon Limited
All news and filings related to Biocon Limited.
View all news & filings- High impact
Biocon Limited Q4 FY26 Earnings Call: Revenue Up 10%, EBITDA Jumps 29%
Biocon Limited reported Q4 FY26 total revenue of ₹4,569 crore, up 10% YoY, and EBITDA of ₹1,073 crore, up 29% YoY. For FY26, revenue reached ₹17,270 crore (up 14% YoY) and EBITDA was ₹3,798 crore (up 25% YoY). The company completed its integration phase and is focusing on execution and value creation.
Read the summary - Low impact
Biocon Files Monitoring Agency Report for Q4FY26 Utilization of QIP Proceeds
Biocon Limited submitted its Monitoring Agency Report for Q4FY26, detailing the utilization of Qualified Institutions Placement (QIP) proceeds. The report, dated May 7, 2026, was reviewed by the Audit Committee and Board. Information is available on the company website.
Read the summary - High impact
Biocon Approves FY26 Results, Recommends 10% Final Dividend, Appoints New Auditors and Directors
Biocon Limited approved its audited financial results for FY26 and recommended a final dividend of 10% (Re. 0.50 per share). The company will appoint S. R. Batliboi & Associates LLP as its new statutory auditors for five years. Several new directors were appointed/re-appointed, and Dr. Anuj Goel and Mr. Susheel Umesh were designated as Senior Management Personnel. Biocon also approved acquiring the remaining ~2% stake in BBL for up to ₹330.73 Crores via a preferential issue.
Read the summary - High impact
Biocon FY26 Revenue ₹17,270 Cr, Profit ₹436 Cr; Recommends ₹0.50 Dividend
Biocon reported Q4FY26 total income of ₹4,569 Cr and FY26 total income of ₹17,270 Cr. FY26 net profit before exceptional items was ₹436 Cr, a 323% YoY increase. The company recommended a final dividend of ₹0.50 per share. Biosimilars revenue grew 16% YoY to ₹10,431 Cr in FY26.
Read the summary - High impact
Biocon Board Approves FY26 Audited Results, Recommends 10% Final Dividend, Appoints New Auditors & Directors
Biocon's Board approved FY26 audited results and recommended a 10% final dividend. It approved S. R. Batliboi & Associates LLP as new statutory auditors for 5 years. The Board also appointed five new Independent Directors and one Non-Executive Non-Independent Director, effective August 1, 2026. Additionally, Biocon will acquire remaining ~2% of BBL for up to Rs. 330.73 Crores via preferential issue.
Read the summary - High impact
Biocon Board Approves FY26 Results, Recommends 10% Final Dividend, and Appoints New Auditors
Biocon Limited's Board approved audited FY26 results and recommended a final dividend of 10% (₹0.50 per share). New statutory auditors, S. R. Batliboi & Associates LLP, were proposed. The company will acquire remaining ~2% of Biocon Biologics Ltd via preferential issue of ~8.79M shares valuing ₹330.73 Cr.
Read the summary - High impact
Biocon Board Approves Financial Results, Recommends 10% Final Dividend, Appoints New Auditors and Directors
Biocon Limited approved its Q4 FY26 audited financial results and recommended a 10% final dividend. The Board appointed S. R. Batliboi & Associates LLP as new statutory auditors for five years. Key management changes include designating Dr. Anuj Goel and Mr. Susheel Umesh as Senior Management Personnel. Several new directors were also recommended for appointment.
Read the summary - High impact
Biocon Approves Final Dividend, Appoints New Auditors and Directors, Acquires Remaining BBL Stake
Biocon's Board approved audited financial results for FY26 and recommended a final dividend of 10% (₹0.50/share). New auditors, S. R. Batliboi & Associates LLP, were recommended. Key management and director changes were approved, including the acquisition of remaining ~2% BBL stake via a ₹330.73 Crore preferential issue of Biocon shares. The 48th AGM is on August 06, 2026.
Read the summary - High impact
Biocon Board Approves FY26 Results, Recommends 10% Final Dividend, Appoints New Auditors & Directors
Biocon's Board approved FY26 audited financial results and recommended a 10% final dividend. New statutory auditors, S. R. Batliboi & Associates LLP, were proposed. Several director appointments and re-appointments were approved, including Ms. Rekha Mehrotra Menon and new independent directors. The company will acquire remaining ~2% of BBL for ~Rs. 330.73 Crores via share swap.
Read the summary - Low impact
Biocon Clarifies Leadership Succession, Kiran Mazumdar-Shaw Continues as Executive Chairperson
Biocon Limited clarifies that Executive Chairperson Kiran Mazumdar-Shaw is not stepping down. The company denies reports of impending leadership succession changes, stating that Ms. Mazumdar-Shaw continues in her role. The management team led by CEO Shreehas Tambe remains in place.
Read the summary - Low impact
Biocon Denies Report on Kiran Mazumdar-Shaw's Successor
Biocon Limited denied a news report about Kiran Mazumdar-Shaw choosing a successor. The company clarified that Ms. Mazumdar-Shaw remains Executive Chairperson, and there are no impending changes in leadership or ownership succession.
Read the summary - Medium impact
Biocon's Biosimilars Site Completes FDA Pre-License Inspection; 5 Procedural Observations Issued
Biocon's biosimilars site in Bengaluru completed a U.S. FDA Pre-License Inspection. The FDA issued five procedural observations, with no data integrity or quality oversight issues noted. Biocon will submit a CAPA plan to address these observations.
Read the summary - Low impact
Biocon Limited Publishes Newspaper Ad for Unclaimed Dividend Campaign
Biocon Limited published newspaper ads on April 28, 2026, for the 'Saksham Niveshak' campaign. Shareholders are urged to update KYC and bank details to claim unpaid/unclaimed dividends before transfer to IEPF. Details are available on Biocon's website. Contact RTA KFintech for assistance.
Read the summary - Medium impact
Biocon Board Meeting on May 7 to Approve FY26 Results & Dividend; Concall on May 8
Biocon Limited will hold a Board Meeting on May 7, 2026, to approve Q4 FY26 financial results and consider dividend. An Earnings Conference Call for Analysts and Investors is scheduled for May 8, 2026. The trading window is closed from April 1 to May 9, 2026.
Read the summary - Medium impact
Biocon's Biosimilars Bosaya™ and Vevzuo™ Receive Health Canada Approval
Health Canada approved Biocon's denosumab biosimilars, Bosaya™ (to Prolia®) and Vevzuo™ (to Xgeva®), on April 3, 2026. These approvals aim to benefit over 2 million adults with osteoporosis and cancer patients with bone metastasis, expanding access to affordable biologic therapies.
Read the summary - Low impact
Biocon Limited Reminds Shareholders to Update KYC Details for Physical Holdings
Biocon Limited is reminding shareholders with physical shareholdings to update their KYC details as per SEBI mandate. Non-compliance by February 06, 2026, may lead to withholding of payments like dividends. Shareholders must submit forms ISR-1 and ISR-2 with supporting documents to the RTA.
Read the summary - Medium impact
Biocon Pharma Limited Receives U.S. FDA Approval for Dapagliflozin Tablets
Biocon Pharma Limited, a subsidiary of Biocon Limited, received U.S. FDA approval for Dapagliflozin Tablets (5 mg and 10 mg). The drug is for type 2 diabetes mellitus, improving glycemic control and reducing heart failure hospitalization risk. Manufacturing will occur at Biocon's FDA-approved facilities.
Read the summary - Low impact
Biocon Limited to Participate in Investor Conference: HSBC Global Investment Summit & Roadshow
Biocon Limited management will participate in the HSBC Global Investment Summit 2026 in Hong Kong from April 14-15, 2026. This will be followed by an Investor Roadshow in Singapore from April 16-17, 2026. No UPSI will be disclosed.
Read the summary - Low impact
Biocon Limited: Certificate Under SEBI (Depositories and Participants) Regulations, 2018 for Q4 FY26
Biocon Limited has submitted a certificate for the quarter ended March 31, 2026, as per SEBI (Depositories and Participants) Regulations, 2018. The company's Registrar and Share Transfer Agent, KFin Technologies Limited, confirmed processing of dematerialization requests within the stipulated timeframe.
Read the summary - Medium impact
Biocon Launches Bosaya™ and Aukelso™ Denosumab Biosimilars in U.S.
Biocon Limited launched Bosaya™ and Aukelso™, denosumab biosimilars, in the U.S. following FDA approval in September 2025. These biosimilars offer affordable treatment options for osteoporosis and bone metastases. Denosumab products generated $5 billion in U.S. sales in 2024.
Read the summary - Low impact
Biocon Limited subsidiary Biosimilar Collaborations Ireland Limited renamed to Biocon Biologics Ireland Limited
Biocon Limited's step-down subsidiary, Biosimilar Collaborations Ireland Limited, has been renamed Biocon Biologics Ireland Limited. The change is effective from March 27, 2026.
Read the summary - Low impact
Biocon India Limited Employees Welfare Trust Appoints New Trustees, Amends Deed
Biocon Limited's Employees Welfare Trust Deed has been amended to change Trustees. Mr. Krishnachar Nandakumar and Ms. Maninder Kapoor Puri resign effective March 31, 2026. Mr. Mukesh Karnath and Mr. Naveen Narayanan are appointed as new Trustees effective April 01, 2026.
Read the summary - High impact
Shreehas Tambe Appointed CEO & MD of Biocon Limited Effective April 1, 2026
Shreehas Tambe appointed CEO & MD of Biocon Limited effective April 1, 2026. Kedar Upadhye named CFO. This follows the integration of Biocon Biologics as a wholly owned subsidiary. Tambe's leadership aims to strengthen the combined biosimilars and generics platform.
Read the summary - Medium impact
Biocon Announces Key Leadership Changes: New CEO & MD Appointed
Biocon Limited's Board approved leadership changes effective April 1, 2026. Mr. Siddharth Mittal resigns as CEO & MD. Mr. Shreehas Pradeep Tambe appointed as new CEO & MD for five years. Mr. Kedar Narayan Upadhye appointed CFO. Mr. Akhilesh Nand designated Head, Governance, Risk and Compliance.
Read the summary - Medium impact
Biocon Appoints New CEO & MD, CFO and Key Management Personnel
Biocon Limited announced leadership changes effective April 1, 2026. Mr. Siddharth Mittal resigns as CEO & MD. Mr. Shreehas Pradeep Tambe appointed new CEO & MD for 5 years. Mr. Mukesh Kamath resigns as Interim CFO. Mr. Kedar Narayan Upadhye appointed new CFO. Mr. Akhilesh Nand appointed Head, Governance, Risk and Compliance.
Read the summary - Medium impact
Biocon Limited Board Approves Key Management Changes
Biocon Limited's Board approved key management changes. Siddharth Mittal resigns as CEO & MD, succeeded by Shreehas Pradeep Tambe from April 1, 2026. Mukesh Kamath resigns as Interim CFO, replaced by Kedar Narayan Upadhye. Akhilesh Nand appointed Head, Governance, Risk and Compliance. Naveen Narayanan and Mandar Shrikant Ghatnekar appointed CHRO and CTO respectively.
Read the summary - Low impact
Biocon Limited Announces Trading Window Closure for Q4 FY26 Results
Biocon Limited's trading window will be closed from April 01, 2026, until 48 hours post the declaration of Q4 FY26 financial results. The board meeting date for results declaration will be announced later.
Read the summary - Medium impact
Biocon Pharma Subsidiary Gets US FDA Approval for Liraglutide Injection ANDA
Biocon Pharma Limited, a subsidiary of Biocon Limited, received US FDA approval for its ANDA for Liraglutide Injection (gVictoza®). This follows a prior approval for Liraglutide injection (gSaxenda®) on February 24, 2026. The approval strengthens Biocon's complex drug product portfolio.
Read the summary - Low impact
Biocon Limited to Participate in JP Morgan India Investor Trip on March 11, 2026
Biocon Limited's management will participate in JP Morgan's India Credit Investor Trip on March 11, 2026. The interactions will be virtual, and no Unpublished Price Sensitive Information will be disclosed. The schedule is subject to change.
Read the summary - Medium impact
Biocon Acquires OCRPS in Subsidiaries Biocon Biosphere & Biocon Pharma for ₹1,153 Crore & ₹2,000 Crore
Biocon Limited acquired OCRPS in subsidiaries Biocon Biosphere for ₹1,153.44 crore and Biocon Pharma for ₹2,000 crore on March 03, 2026. The acquisitions are for working capital and capex needs. Both subsidiaries are wholly-owned.
Read the summary - Low impact
Biocon Limited to Participate in Goldman Sachs India Pharma Corporate Days on March 6, 2026
Biocon Limited announced its participation in the Goldman Sachs India Pharma Corporate Days event on March 6, 2026. The interaction will be virtual, and no Unpublished Price Sensitive Information will be disclosed.
Read the summary - Medium impact
Biocon Limited Announces Investor Presentation for Analyst Meets on Feb 25-26, 2026
Biocon Limited is holding investor meets on February 25-26, 2026, to present its investor presentation. The presentation details the company's integrated business strategy, financial restructuring including a ₹4,500 crore QIP, and improved debt metrics. It highlights strong performance in Biosimilars and Generics, with significant pipeline development in Oncology, Immunology, and GLP-1s.
Read the summary - High impact
Biocon Secures US FDA Approval for Weight Management Drug Liraglutide
Biocon Limited received U.S. FDA approval for its Liraglutide Injection (gSaxenda®) for chronic weight management. The drug-device combination is an adjunct to diet and exercise. The U.S. market for GLP-1 in weight loss was valued at US $127 million in December 2025.
Read the summary - High impact
Biocon Limited Q3 FY26 Earnings Call Transcript Released
Biocon Limited released its Q3 FY26 earnings call transcript, detailing a 9% YoY revenue growth to ₹4,173 crore and a 21% YoY EBITDA increase to ₹1,221 crore. The company highlighted the planned merger of Biocon Biologics with Biocon, valued at USD 5.5 billion. Key updates include new biosimilar oncology assets and the launch of generic Liraglutide. Credit ratings were upgraded, and structured debt was retired.
Read the summary - Low impact
Biocon Limited to Participate in Investor Conferences in February 2026
Biocon Limited will participate in two investor conferences: the IIFL 17th Entrepreneurial India Conference on Feb 25, 2026, and the Kotak Chasing Growth Conference on Feb 26, 2026, both in Mumbai. Management will engage in one-on-one and group meetings. No UPSI will be disclosed.
Read the summary - Low impact
Biocon Limited Publishes Newspaper Advertisement for Q3 FY26 Financial Results
Biocon Limited published its financial results for Q3 FY26 and the nine months ended December 31, 2025, via newspaper advertisements on February 14, 2026. Full results are accessible via QR code, weblink, and the company website. Board approval was received on February 12, 2026.
Read the summary - Low impact
Biocon Limited Releases Q3 FY26 Earnings Call Audio/Video Recording
Biocon Limited has made available the audio and video recordings of its Q3 FY26 Earnings Call, held on February 13, 2026. The recordings can be accessed via a link on the company's website.
Read the summary - High impact
Biocon Q3 FY26 Earnings: Revenue Up 9% YoY to ₹4,173 Cr, Net Profit Jumps 844% YoY to ₹124 Cr
Biocon Limited reported Q3 FY26 results with revenue from operations at ₹4,173 crore (up 9% YoY). Core EBITDA increased by 21% YoY to ₹1,221 crore. Net Profit (Before exceptional items) surged 844% YoY to ₹124 crore. The company is focused on sustainable growth and margin expansion.
Read the summary - Low impact
Biocon Limited: Monitoring Agency Report for Q4FY26 Shows No Deviation in QIP Fund Utilization
Biocon Limited's Monitoring Agency Report for Q4FY26 confirms no deviation in the utilization of funds raised via QIP. The QIP, amounting to ₹45,000 million (4,500 crore), was for debenture purchases and debt repayment. As of December 31, 2025, ₹23,652.15 million (2,365.215 crore) was utilized, with ₹6,257.85 million (625.785 crore) remaining.
Read the summary - High impact
Biocon Q3FY26 Revenue at ₹4,173 Cr, Net Profit ₹144 Cr
Biocon Limited reported Q3FY26 operating revenue of ₹4,173 crore, up 9% YoY. EBITDA increased 21% to ₹951 crore, and Net Profit surged 475% to ₹144 crore. The company fully integrated Biocon Biologics for approximately USD 5.5 billion and raised nearly USD 1 billion through two QIPs. Credit ratings for Biocon Biologics were upgraded.
Read the summary - Medium impact
Biocon Board Approves Q3 FY26 Results; Advances Biologics Integration
Biocon Limited's Board approved Q3 FY26 results. The company also received in-principle approval to acquire the remaining ~2% stake in Biocon Biologics Limited (BBL) from employees and other shareholders via preferential equity allotment, aiming to make BBL a wholly owned subsidiary.
Read the summary - Medium impact
Biocon Limited Board Approves Financial Results and Biologics Integration
Biocon Limited's Board approved un-audited financial results for Q3 FY26. The company received in-principle approval to acquire the remaining ~2% stake in Biocon Biologics Limited (BBL), making it a wholly-owned subsidiary. This will be discharged via preferential allotment of Biocon shares.
Read the summary - High impact
Biocon Limited Approves Financial Results and Full Integration of Biocon Biologics
Biocon Limited's Board approved Q3 FY26 results and the acquisition of remaining ~2% stake in Biocon Biologics (BBL) to make it a wholly-owned subsidiary. Consolidated revenue rose to ₹41,730 million, but net loss was ₹518 million. Standalone revenue increased to ₹6,213 million with a net loss of ₹764 million.
Read the summary - Medium impact
Fitch Ratings Upgrades Biocon Biologics Outlook to 'Positive' from 'Stable'
Fitch Ratings has upgraded Biocon Biologics' outlook to 'Positive' from 'Stable' and affirmed its IDR at 'BB-'. The rating on USD 800 million secured notes was also affirmed at 'BB'. The positive outlook is driven by expectations of reduced financial leverage.
Read the summary - Low impact
Biocon Sets January 29, 2026 Record Date for ₹200 Crore Commercial Paper Buyback
Biocon Limited has set January 29, 2026, as the record date for the buyback of its listed Commercial Paper. The buyback is for an issue size of ₹200 Crore, with the redemption scheduled for January 30, 2026.
Read the summary - Low impact
Biocon Limited Sets Record Date for Buyback of ₹1,800 Crore Commercial Paper
Biocon Limited has set January 29, 2026, as the record date for the buyback of its listed Commercial Paper (ISIN INE376G14040). The buyback of the ₹1,800 Crore issue is scheduled for January 30, 2026.
Read the summary - Low impact
Biocon API Facility Receives VAI Status from US FDA Post-Inspection
Biocon Limited's API facility in Andhra Pradesh has received a Voluntary Action Indicated (VAI) status from the US FDA. This status was assigned following an inspection that took place from November 3rd to November 7th, 2025.
Read the summary - High impact
S&P Global Upgrades Biocon Biologics Credit Rating to 'BB+', Outlook to Stable
S&P Global Ratings upgraded Biocon Biologics' credit rating to 'BB+' from 'BB' with a stable outlook. This follows Biocon's equity issuance to settle US$1 billion in CCPS to Viatris, funded by US$460 million in fresh equity. The upgrade reflects simplified capital structure and expected earnings growth from new product launches.
Read the summary - Low impact
Biocon Limited Files Quarterly Certificate for Commercial Paper Use of Proceeds
Biocon Limited submitted a quarterly certificate on January 21, 2026, confirming the use of Commercial Paper proceeds and compliance with listing conditions for the quarter ended December 31, 2025, as per SEBI Master Circular.
Read the summary - Medium impact
Biocon Completes Acquisition of Remaining Biocon Biologics Shares from Mylan for $200 Million
Biocon Limited completed the acquisition of the remaining 7,18,34,691 equity shares of Biocon Biologics Limited from Mylan Inc. for USD 200 million on January 21, 2026. This brings Biocon's total stake to approximately 98% of BBL's paid-up equity share capital.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio